Details

Autor(en) / Beteiligte

• Kang, Sora
• Cho, Hyungwoo
• Kim, Shin
• Lee, Kyoungmin
• Kang, Eun Hee
• Park, Jung Sun
• Lee, Yoon Sei
• Park, Chan-Sik
• Go, Heounjeong
• Huh, Jooryung
• Ryu, Jin Sook
• Lee, Sang-Wook
• Kim, Seok Jin
• Kim, Won Seog
• Yoon, Sang Eun
• Ko, Young Hyeh
• Suh, Cheolwon

Titel

A New Prognostic Index for Extranodal Natural Killer/T-Cell Lymphoma:Incorporation of Serum β-2 Microglobulin to PINK

Ist Teil von

• Cancer Research and Treatment, 2023, 55(1), , pp.314-324

Ort / Verlag

Korea (South): Korean Cancer Association

Erscheinungsjahr

2023

Quelle

MEDLINE

Beschreibungen/Notizen

• Prognostic Index for Natural Killer Lymphoma (PINK) is the most widely accepted prognostic model for patients withextranodal natural killer/T-cell lymphoma (ENKTL) treated with non-anthracycline-based therapy. We aimed to evaluate the prognostic implications of serum β-2 microglobulin (β2M) in the context of PINK and proposed a new prognostic model. A total of 138 patients who were newly diagnosed with ENKTL and treated with non-anthracycline-based chemotherapy were identified. The cut-off value of high serum β2M was calculated by maximal-chi square methods (4.1 mg/L). A new prognostic model incorporating serum β2M into PINK was proposed and validated in an independent validation cohort (n=88). The patients' median age was 53.5 years (range, 19 to 80 years). Patients with high serum β2M levels had significantly worse overall survival (OS) and progression-free survival (PFS). In multivariate analysis, high serum β2M was an independent adverse prognostic factor for OS. A new PINK-B (Prognostic Index for Natural Killer Lymphoma-serum β-2 microglobulin) model stratifiedpatients into three groups with distinct OS and PFS in the training cohort (3-year OS, 84.1% [95% confidence interval, 75.1 to 94.2], 46.8% [36.1 to 60.8] and 17.6% [6.3 to 49.2] for the low-, intermediate, and high-risk groups, respectively; 3-year PFS, 70.6% [59.4 to 83.8], 35.9% [25.9 to 49.8], and 7.35% [1.1 to 46.7] for the low-, intermediate-, and high-risk groups, respectively). The PINK-B model was further validated in an independent cohort. Serum β2M is an independent prognostic factor for ENKTL patients. The new serum β2M-based prognostic model may be useful for identifying ultra-high-risk patients, and it can easily be adopted into daily clinical practice.